Both the stocks have underperformed with mid-single-digit growth year-to-date, compared to 22% growth for the broader S&P 500. While Boston Scientific saw a fall in demand for medical devices and supplies during the pandemic, due to fewer surgical procedures, Veeva's business expanded with increased adoption of digital communication channels. In fact, Boston Scientific's revenue declined 8% during the pandemic, while Veeva's revenue expanded a solid 28%. However, there is more to the comparison. Let's step back to look at the fuller picture of the relative valuation of the two companies by looking at historical revenue growth as well as operating margin growth. Our dashboard Boston Scientific vs Veeva : Similar Operating Income; Which Stock Is A Better Bet? has more details on this. Parts of the analysis are summarized below.